{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T21:41:46Z","timestamp":1769290906237,"version":"3.49.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Neuropsychiatric systemic lupus erythematosus (NPSLE) manifesting as Guillain-Barr\u00e9 syndrome (GBS) is exceptionally rare, with only 28 documented cases in medical literature, and current biological therapies show limited efficacy. We report a 34-year-old woman who presented with progressive quadriparesis, bilateral ptosis, and facial palsy developing over one month. Laboratory investigations revealed marked B-cell dysregulation with elevated immunoglobulin G (24.30 g\/L, normal 7-16), positive antinuclear antibodies (1:320), anti-double-stranded DNA antibodies (128 IU\/ml, normal &amp;lt;20), anti-ribosomal P antibodies (450 AU\/ml, normal &amp;lt;20), and hypocomplementemia (C3 1.10 g\/L, C4 0.28 g\/L). Cerebrospinal fluid analysis showed cytoalbuminologic dissociation (protein 1314 mg\/L, cells 1\u00d710\n                    <jats:sup>6<\/jats:sup>\n                    \/L), and nerve conduction studies confirmed acute inflammatory demyelinating polyradiculoneuropathy. Following inadequate response to intravenous immunoglobulin monotherapy, combination treatment was initiated with methylprednisolone (40mg daily), cyclophosphamide (0.6g biweekly), hydroxychloroquine, and telitacicept (160mg weekly), a novel dual inhibitor of B lymphocyte stimulator and a proliferation-inducing ligand that simultaneously targets B cells and plasma cells. At six-month follow-up, the patient achieved complete neurological recovery with significant laboratory improvements: immunoglobulin G decreased 61.6% to 9.34 g\/L, anti-double-stranded DNA antibodies decreased 82.8% to 22 IU\/ml, erythrocyte sedimentation rate normalized from 63 to 8 mm\/h, and complement levels recovered. Corticosteroids were successfully tapered to 4mg daily without disease flare. This first report of telitacicept use in NPSLE-GBS demonstrates that dual BLyS\/APRIL inhibition can achieve complete remission in refractory cases, offering a promising therapeutic approach that warrants further investigation in controlled trials.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1726901","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:08:11Z","timestamp":1769170091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Complete remission of Guillain-Barr\u00e9 syndrome in neuropsychiatric lupus with telitacicept"],"prefix":"10.3389","volume":"17","author":[{"given":"Yunqi","family":"Bao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nannan","family":"Gai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4%253C599::AID-ANR2%253E3.0.CO;2-F","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-023-10075-w","article-title":"Cyclophosphamide in the treatment of systemic lupus erythematosus-related guillain-barr\u00e9 Syndrome: A systematic review of case reports","volume":"18","author":"Xiong","year":"2023","journal-title":"J Neuroimmune Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314552115","article-title":"Clinical and electrophysiological characteristics of symmetric polyneuropathy in a cohort of systemic lupus erythematosus patients","volume":"24","author":"Jasmin","year":"2015","journal-title":"Lupus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.38302","article-title":"Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period","volume":"66","author":"Oomatia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0156-8","article-title":"Neuropsychiatric lupus: new mechanistic insights and future treatment directions","volume":"15","author":"Schwartz","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.40764","article-title":"Psychosis in systemic lupus erythematosus: results from an international inception cohort study","volume":"71","author":"Hanly","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B11","article-title":"RemeGen announces preliminary results of phase III confirmatory study of telitacicept for treatment of systemic lupus erythematosus (SLE) in China","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e16322","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13904","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study","volume":"28","author":"Ding","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2023.02.007","article-title":"Guillain-Barre syndrome as the initial presentation of systemic lupus erythematosus: Case report with a systematic and literature review","author":"Bhoi","year":"2023","journal-title":"Med J Armed Forces India"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21539","article-title":"Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis","volume":"54","author":"Karassa","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102780","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: A review","volume":"20","author":"Carri\u00f3n-Barber\u00e0","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e2149675","DOI":"10.1002\/eji.202149675","article-title":"Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches","volume":"53","author":"Merino-Vico","year":"2023","journal-title":"Eur J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1602800","article-title":"Dual BLyS\/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report","volume":"16","author":"Dai","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1726901\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:08:13Z","timestamp":1769170093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1726901\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2026.1726901"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1726901","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1726901"}}